REGEN4HD, an early stage safety trial at UCI Health, has enrolled 21 patients to test hNSC 01, lab grown neural stem cells derived from embryonic stem cells and designed to replace lost neurons and protect the ones still standing in a fatal inherited brain disorder with no…
Huntington's disease is a fatal, inherited brain disorder that usually strikes in a person's thirties or forties, stripping away movement control, planning, and mood over the decades that follow. For two decades, the field's best bets have been small molecules that try to quiet the toxic protein driving the disease, or antisense drugs that try to silence the gene that produces it. A different approach has now reached its first human test at UCI Health, the clinical arm of the University of California, Irvine. This spring, surgeons implanted lab-grown neural stem cells into the brain of the first patient enrolled in REGEN4HD, a 21-person safety study of an embryonic-stem-cell-derived therapy called hNSC-01. A second patient is scheduled for July.
The shift matters because two decades of drugs that target huntingtin have not produced a treatment that slows the disease. Antisense oligonucleotides, small-molecule splicing modifiers, and gene therapies have all reached the clinic without yielding one, as covered in the GenEngNews recap of the UCI launch. hNSC-01 is built on a different bet. Instead of asking damaged circuits to do less harm, it asks new cells to move in.
In mouse studies, the cells did four things at once. They protected existing neurons from dying. They replaced lost ones. They helped rebuild the circuits those neurons form. And they released brain-derived neurotrophic factor, a protein that helps neurons survive, while reducing the buildup of the toxic huntingtin protein that drives the disease. The product is a human neural stem cell line derived from embryonic stem cells, the master cells capable of turning into any tissue type, manufactured at the UC Davis GMP facility, a clinical-grade cell-manufacturing operation. The cells are delivered through a stereotactic brain-mapping and targeting system that lets surgeons place them with millimeter precision during a roughly six-hour procedure.
REGEN4HD is built to answer a narrow, falsifiable question: can the surgery and the implant be tolerated? Twelve of the 21 enrolled patients will enter a Phase Ib dose-escalation arm, with the remaining nine moving into a Phase IIa expansion cohort once the higher dose is cleared. Patients are adults 18 to 65 with early-stage Huntington's. The primary endpoints are safety, not efficacy. If the Phase Ib cohort cannot tolerate the surgery itself, the program faces a clear setback before any question about cell behavior gets answered.
The line of work behind the trial has unusual translational provenance for an academic-led program. The California Institute for Regenerative Medicine has funded the line of work through two awards, first for an hESC-derived hNSC therapeutic and then for an hNSC development candidate, a two-stage commitment that bridged preclinical work and the IND-enabling studies regulators require before a first human dose. A $12 million grant announced in December 2025 financed the clinical phase itself.
Leslie M. Thompson, a UC Irvine professor of psychiatry and human behavior who has shepherded the program from the bench, framed the launch in terms of partnership with the patient community. "We are grateful to our patients and their incredible families for their bravery to provide hope for others with very few options," she said in the UCI announcement. Ravi Rajmohan, the trial's principal investigator at UCI Health, kept the read-out in honest terms. "The first patient intervention went very well," he said. "To date, they haven't reported any serious adverse events. This trial may help us move one step closer to a future with available treatments that could potentially slow the progression of Huntington's disease."
The framing matters because it sets the right scale for what to expect. A successful Phase Ib/IIa safety trial would not change the standard of care for years. Efficacy readouts, dose selection, and a registrational program all still lie ahead. But the door that opened at UCI Health this spring is one that two decades of small-molecule and gene-silencing programs never managed to open for Huntington's families. Whether the cells survive, integrate, and behave the way they did in mice is the question the remaining patients in the trial are now being asked to help answer.